Ecaterina Ileana Dumbrava

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

Seyed Pairawan, Ming Zhao, Erkan Yuca et al. · Breast Cancer Research · 2021 · 68 citations · Full text

Medicine, Oncology, Pharmacology +13

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss

Nicci Owusu‐Brackett, Ming Zhao, Argun Akçakanat et al. · Oncotarget · 2020 · 24 citations · Full text

Medicine, Cancer Biology, Oncology +17

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang et al. · Experimental Hematology and Oncology · 2020 · 18 citations · Full text

Medicine, Oncology, Pharmacology +14

Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations

Ecaterina Ileana Dumbrava, Lauren Brusco, Molly S. Daniels et al. · JCO Precision Oncology · 2019 · 17 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Ecaterina Ileana Dumbrava, Manish Sharma, Richard D. Carvajal et al. · Cancer Research · 2021 · 17 citations

Medicine, Oncology, Pharmacology +17